Key takeaways
Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide) are both used to treat HIV, but they have some key differences. Stribild is a single-tablet regimen that includes an integrase inhibitor, two NRTIs, and a booster, while Descovy contains only two NRTIs and must be taken with another medication for complete HIV treatment. Stribild must be taken with food, whereas Descovy can be taken with or without food. Descovy is also preferred for HIV prevention (PrEP) but is not effective for receptive vaginal sex, while Stribild can be used for post-exposure prophylaxis (PEP). Stribild has more potential side effects, including kidney and bone problems, and is not recommended for people with kidney or liver issues. Descovy is considered safer for the kidneys and bones but still requires regular monitoring. Both medications can worsen hepatitis B if stopped suddenly, so it's important to follow your healthcare provider's instructions closely.
